Lirum Therapeutics, Inc. Stock

Stocks

04-20	Lirum Therapeutics Announces Positive Lx-101 Data Selected for Presentation At the 2026 American Association for Cancer Research Annual Meeting	CI
21/10/25	Lirum Therapeutics, Inc. Announces FDA" Study May Proceed" Letter Enabling Inclusion of Lx-101 in the Rapid Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor	CI
07/05/25	Lirum Therapeutics Announces New Lx-101 Data in Thyroid Eye Disease Selected for Presentation At the Association for Research in Vision and Ophthalmology 2025 Annual Meeting	CI
29/04/25	Lirum Therapeutics, Inc. Announces New Positive Data on LX-101 Against Increasingly Wide Variety of Cancer Types Selected for Presentation at 2025 AACR Annual Meeting in Chicago	CI
04/03/25	Lirum Therapeutics, Inc. Presents Positive Data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress	CI

21/10/25

Manager	Title	Age	Since
Peter McDonald CEO	Chief Executive Officer	52	01/04/2023
Matt Hoberman COO	Chief Operating Officer	-	01/06/2022
Stephen Lichaw PRN	Corporate Officer/Principal	-	01/08/2022